Gonadorelin vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
GonadorelinAnti-Aging & Longevity
FOXO4-DRI- Summary
- Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- SubQ, Intranasal
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 100 mcg
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Twice daily (every 12 hours)
- 3 consecutive days per cycle
- Key Benefits
- Maintains testicular size during TRT
- Preserves fertility and sperm production during testosterone use
- Stimulates endogenous LH/FSH production
- Maintains HPG axis function during exogenous hormone use
- Used for HCG-free TRT protocols
- Helps restart natural testosterone production (PCT)
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Injection site reactions
- Headache
- Nausea at initiation
- Tachycardia (rare)
- +1 more
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —